Placenta growth factor (PIGF) levels in women with preeclampsia and intrauterine growth restriction: is PIGF a marker for fetal well-being?

2003 ◽  
Vol 189 (6) ◽  
pp. S166
Author(s):  
Dietmar Schlembach ◽  
Ruth Sengenberger ◽  
Wenzel Wallner ◽  
Britta Meurer ◽  
Matthias W Beckmann ◽  
...  
Keyword(s):  
Growth Factor ◽  
Intrauterine Growth Restriction ◽  
Well Being ◽  
Growth Restriction ◽  
Placenta Growth Factor ◽  
Intrauterine Growth

scholarly journals Vascular Endothelial Growth Factor and Placenta Growth Factor in Intrauterine Growth-Restricted Fetuses and Neonates

2005 ◽  
Vol 2005 (5) ◽  
pp. 293-297 ◽  
Author(s):  
Ariadne Malamitsi-Puchner ◽  
Theodora Boutsikou ◽  
Emmanuel Economou ◽  
Angeliki Sarandakou ◽  
Evangelos Makrakis ◽  
...  
Keyword(s):  
Vascular Endothelial Growth Factor ◽  
Growth Factor ◽  
Intrauterine Growth Restriction ◽  
Vascular Endothelial ◽  
Placenta Growth Factor ◽  
Placental Function ◽  
Intrauterine Growth ◽  
Appropriate For Gestational Age ◽  
Endothelial Growth Factor ◽  
Circulating Levels

The angiogenic factors vascular endothelial growth factor (VEGF) and placenta growth factor (PlGF) are respectively up- and downregulated by hypoxia. We aimed to study circulating levels of the above factors in intrauterine growth restriction (IUGR) and to correlate their levels with the customized centiles of the infants. The study included 25 IUGR and 25 appropriate for gestational age (AGA) full-term, singleton infants and their mothers. Maternal (MS), fetal (UC), and neonatal day 1 (N1) and 4 (N4) blood was examined. MS and N1 PlGF, as well as UC VEGF levels correlated with the customized centiles of the infants (r=0.39,P=.007,r=0.34,P=.01, andr=−0.41,P=.004, resp). Furthermore, UC, N1, and N4 VEGF levels were higher in girls (r=0.36,P=.01,r=0.33,P=.02, andr=0.41,P=.005resp). In conclusion, positive and negative correlations of examined factors with the customized centiles of the infant could rely on placental function and intrauterine oxygen concentrations—both being usually lower in IUGR cases—while higher VEGF levels in girls should possibly be attributed to the stimulating action of estrogens.

scholarly journals Placental Growth Factor for the Prediction of Adverse Outcomes in Patients with Suspected Preeclampsia or Intrauterine Growth Restriction

PLoS ONE ◽  
2012 ◽  
Vol 7 (11) ◽  
pp. e50208 ◽  
Author(s):  
Jeanne Sibiude ◽  
Jean Guibourdenche ◽  
Marie-Danielle Dionne ◽  
Camille Le Ray ◽  
Olivia Anselem ◽  
...  
Keyword(s):  
Growth Factor ◽  
Intrauterine Growth Restriction ◽  
Placental Growth Factor ◽  
Adverse Outcomes ◽  
Growth Restriction ◽  
Intrauterine Growth

scholarly journals AMPK activation in pregnant human myometrial arteries from high-altitude and intrauterine growth-restricted pregnancies

2020 ◽  
Vol 319 (1) ◽  
pp. H203-H212
Author(s):  
Ramón A. Lorca ◽  
Christopher J. Matarazzo ◽  
Elise S. Bales ◽  
Julie A. Houck ◽  
David J. Orlicky ◽  
...  
Keyword(s):  
High Altitude ◽  
Gestational Age ◽  
Intrauterine Growth Restriction ◽  
Well Being ◽  
Growth Restriction ◽  
Ampk Activation ◽  
Intrauterine Growth ◽  
Mother And Child ◽  
Appropriate For Gestational Age

Intrauterine growth restriction (IUGR) impairs infant well being and increases susceptibility to later-in-life diseases for mother and child. Our study reveals a novel role for AMPK in vasodilating the myometrial artery (MA) from women residing at high altitude (>2,500 m) with appropriate for gestational age pregnancies but not in IUGR pregnancies at any altitude.

Differential regulation of igf1 and igf1r mRNA levels in the two hepatic lobes following intrauterine growth restriction and its treatment with intra-amniotic insulin-like growth factor-1 in ovine fetuses

2010 ◽  
Vol 22 (8) ◽  
pp. 1188 ◽  
Author(s):  
Revati A. Darp ◽  
Hendrina A. de Boo ◽  
Hui Hui Phua ◽  
Mark H. Oliver ◽  
José G. B. Derraik ◽  
...  
Keyword(s):  
Growth Factor ◽  
Intrauterine Growth Restriction ◽  
Venous Blood ◽  
Growth Restriction ◽  
Mrna Levels ◽  
Insulin Like Growth Factor ◽  
Hepatic Lobe ◽  
Intrauterine Growth ◽  
The Right ◽  
Gut Maturation

Intrauterine growth restriction (IUGR) has life-long health implications, yet there is no effective prenatal treatment. Daily intra-amniotic administration of insulin-like growth factor (IGF)-1 to IUGR fetal sheep improves fetal gut maturation but suppresses hepatic igf1 gene expression. Fetal hepatic blood supply is regulated, in part, by shunting of oxygen- and nutrient-rich umbilical venous blood through the ductus venosus, with the left hepatic lobe predominantly supplied by umbilical venous blood and the right hepatic lobe predominantly supplied by the portal circulation. We hypothesised that: (1) once-weekly intra-amniotic IGF-1 treatment of IUGR would be effective in promoting gut maturation; and (2) IUGR and its treatment with intra-amniotic IGF-1 would differentially affect igf1 and igf1r mRNA expression in the two hepatic lobes. IUGR fetuses received 360 µg IGF-1 or saline intra-amniotically once weekly from 110 until 131 days gestation. Treatment of IUGR fetuses with IGF-1 reversed impaired gut growth. In unembolised, untreated control fetuses, igf1 mRNA levels were 19% lower in the right hepatic lobe than in the left; in IUGR fetuses, igf1 and igf1r mRNA levels were sixfold higher in the right lobe. IGF-1 treatment reduced igf1 and igf1r mRNA levels in both lobes compared with IUGR fetuses. Thus, weekly intra-amniotic IGF-1 treatment, a clinically feasible approach, reverses the impaired gut development seen in IUGR. Furthermore, igf1 and igf1r mRNA levels are differentially expressed in the two hepatic lobes and relative expression in the two lobes is altered by both IUGR and intra-amniotic IGF-1 treatment.

Sign in / Sign up

Export Citation Format

Share Document